
## Finished Products list Probiotic based



Cerbios is on the market for over 40 years with its proprietary probiotic strain Enterococcus lactis SF68<sup>®</sup>, (formerly E.faecium) registered as drug product (e-CTD dossier) for the treatment of diarrhea and dysbiosis (more than 40 clinical trials published). Given the increasing interest on microbiota and role of probiotics on prevention, diagnosis and treatment of various pathologies, Cerbios is engaged to further investigate potential applications of its strain in different areas:

Pathologies	R&D & proof of concept	Industrial Validation	Clinical trial Scientific evd.	Registration file ready for submission
ACNE & SEBORRHEIC DERMATITIS	$\oslash$	$\oslash$	$\oslash$	$\oslash$
IMMUNE SYSTEM	$\bigcirc$	$\odot$	$\odot$	$\odot$
CHOLESTEROL OBESITY- METABOLIC SYNDROME	$\oslash$	$\odot$	Scheduled for Q3 2022	Scheduled for Q4 2022
IBS IRRITABLE BOWEL SYNDROME	$\bigcirc$	$\oslash$	Scheduled for Q4 2022	Scheduled for Q4 2022

• E. lactis SF68<sup>®</sup> combined with other different functional ingredients.

- Cerbios supports efficacy of its Products with clinical trials and scientific evidences.
- Regulatory status: FS or FSMPs.



**Cerbios-Pharma SA** Via Figino 6 6917 Barbengo SWITZERLAND 
 Phone
 +41 (0)91 985 63 11

 Fax
 +41 (0)91 985 63 25

 E-mail
 sales@cerbios.ch

 Web
 www.cerbios.swiss